← Back to Screener
Adicet Bio, Inc. Common Stock (ACET)
Price$7.26
Value ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-37.92%
Price vs S&P 500 (4W)-15.08%
VGM Score59.89
Market Capitalization$67.87M
All Metrics
Book Value / Share (Quarterly)$14.59
P/TBV (Annual)2.20x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.55
Price vs S&P 500 (YTD)-21.93%
Net Profit Margin (TTM)-93.15%
EPS (TTM)$-16.51
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-16.51
EPS (Annual)$-1.33
ROI (Annual)-62.70%
Net Profit Margin (5Y Avg)-548.85%
Cash / Share (Quarterly)$14.34
ROA (Last FY)-53.13%
EBITD / Share (TTM)$-14.85
ROE (5Y Avg)-44.86%
Operating Margin (TTM)-91.40%
Cash Flow / Share (Annual)$-10.12
P/B Ratio0.48x
P/B Ratio (Quarterly)0.47x
Net Income / Employee (Annual)$-1,147,100
EV / Revenue (TTM)0.84x
Net Interest Coverage (TTM)-689.22x
ROA (TTM)-65.44%
EPS Incl Extra (Annual)$-1.33
Current Ratio (Annual)7.47x
Quick Ratio (Quarterly)7.54x
3-Month Avg Trading Volume0.14M
52-Week Price Return-39.45%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.63
P/S Ratio (Annual)2.72x
Asset Turnover (Annual)0.08x
52-Week High$17.44
Operating Margin (5Y Avg)-566.93%
EPS Excl Extra (Annual)$-1.33
CapEx CAGR (5Y)11.91%
Tangible BV CAGR (5Y)40.58%
26-Week Price Return-29.99%
Quick Ratio (Annual)7.38x
13-Week Price Return-2.68%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)7.66x
Enterprise Value$32.61M
Asset Turnover (TTM)0.13x
Book Value / Share Growth (5Y)24.40%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-279.27%
Cash / Share (Annual)$16.54
3-Month Return Std Dev75.17%
Net Income / Employee (TTM)$-1,067,000
ROE (Last FY)-62.70%
EPS Basic Excl Extra (Annual)$-1.33
Receivables Turnover (TTM)249.90x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-16.51
Receivables Turnover (Annual)270.16x
ROI (TTM)-79.92%
P/S Ratio (TTM)1.75x
Pretax Margin (5Y Avg)-554.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.63
Price vs S&P 500 (52W)-63.82%
Year-to-Date Return-13.78%
5-Day Price Return-17.31%
EPS Normalized (Annual)$-1.33
ROA (5Y Avg)-37.04%
Net Profit Margin (Annual)-279.27%
Month-to-Date Return-22.02%
Cash Flow / Share (TTM)$-3.21
EBITD / Share (Annual)$-1.38
Operating Margin (Annual)-290.32%
ROI (5Y Avg)-44.86%
EPS Basic Excl Extra (TTM)$-16.51
P/TBV (Quarterly)2.20x
P/B Ratio (Annual)0.51x
Pretax Margin (TTM)-93.36%
Book Value / Share (Annual)$16.61
Price vs S&P 500 (13W)-10.94%
Beta1.67x
Revenue / Share (TTM)$0.00
ROE (TTM)-80.35%
52-Week Low$6.01
vGradeA
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.88est. -3.17
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACETAdicet Bio, Inc. Common Stock | A | — | D | $7.26 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. ADI-001, its lead candidate, is a CD20-targeting CAR T cell therapy in development for relapsed or refractory B cell lymphomas and autoimmune indications. The company's pipeline also includes ADI-270, a preclinical CAR T program targeting CD70 for renal cell carcinoma and other solid tumors.